Taurolidine lock - experience from the West of Scotland.
Paul S
PS
Cullis
Ruth F
RF
McKee
D000293:Adolescent; D000328:Adult; D000368:Aged; D000890:Anti-Infective Agents / Q000008:administration & dosage / Q000627:therapeutic use*; D000925:Anticoagulants / Q000008:administration & dosage / Q000627:therapeutic use; D055499:Catheter-Related Infections / Q000453:epidemiology / Q000382:microbiology / Q000517:prevention & control*; D005260:Female; D006493:Heparin / Q000008:administration & dosage / Q000627:therapeutic use; D006801:Humans; D008297:Male; D008875:Middle Aged; D016331:Parenteral Nutrition, Home / Q000009:adverse effects; D012189:Retrospective Studies; D012606:Scotland / Q000453:epidemiology; D013654:Taurine / Q000008:administration & dosage / Q000031:analogs & derivatives* / Q000627:therapeutic use; D013829:Thiadiazines / Q000008:administration & dosage / Q000627:therapeutic use*; D013997:Time Factors; D055815:Young Adult
D000890:Anti-Infective Agents; D000925:Anticoagulants; D013829:Thiadiazines; D013654:Taurine; C012566:taurolidine; D006493:Heparin